177Lu-FAP-2286 Targeted Radionuclide Therapy in Advanced Pancreatic Cancer: A Real-World Retrospective Salvage Study

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Pancreatic cancer remains a significant challenge with limited treatment options for refractory or treatment-ineligible patients.
• Targeted radionuclide therapy (TRT) offers a novel approach by delivering radiation directly to cancer cells.

Purpose of the Study:

• To evaluate the efficacy, safety, and survival outcomes of 177Lu-FAP-2286 TRT.
• To assess its potential as a salvage therapeutic option for pancreatic cancer.

Main Methods:

• Retrospective single-center study of 22 patients with pancreatic malignancies treated with 177Lu-FAP-2286.
• Endpoints included safety (CTCAE v5.0), symptom scores, performance status, quality of life (EORTC QLQ-C30), radiologic response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS).

Main Results:

• 177Lu-FAP-2286 demonstrated a favorable safety profile with manageable toxicities.
• Significant improvements observed in pain scores, Karnofsky Performance Status (KPS), and quality of life domains.
• Disease control rate (DCR) was 40.9% in the intent-to-treat population and 75% in the evaluable subgroup.
• Median OS and PFS were 127 and 109 days, respectively. Post-treatment KPS improvement correlated with improved OS and PFS.

Conclusions:

• 177Lu-FAP-2286 shows favorable safety and meaningful symptom palliation in refractory pancreatic cancer.
• Supports further clinical investigation as a salvage therapeutic option for pancreatic cancer patients.